Abstract
With few exceptions, epidemiological studies have found that individuals who take nonsteroidal antiinflammatory drugs (NSAIDs) have a reduced risk of colorectal adenomas and carcinoma. Similarly, randomized studies in patients with familial adenomatous polyposis have uniformly found that NSAIDs can lead to polyp regression and prevention of new polyps, and trials in patients with sporadic adenomas document that aspirin reduces the risk of adenoma recurrence. Together these data provide convincing evidence for the chemopreventive efficacy of NSAIDs in the large bowel.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Allison M, Garland C, Chlebowski R, et al (2006) The association between aspirin use and the incience of colorectal cancer in women. Am J Epidemiol 164:567–575
Arber N, Eagle CJ, Spicak J, et al (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885–895
Baron JA (2003) Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res 37:1–24
Baron JA, Sandler RS (2000) Nonsteroidal anti- inflammatory drugs and cancer prevention. Annu Rev Med 51:511–523
Baron JA, Cole B F, Sandler RS, et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891–899
Baron JA, Sandler RS, Bresalier RS, et al (2006) A randomized trial of rofecoxib for the chemopre- vention of colorectal adenomas. Gastroenterology 131:1674–1682
Benamouzig R, Deyra J, Martin A, et al (2003) Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-Year results of the APACC trial. Gastroenterology 125:328–336
Bertagnolli MM, Eagle CJ, Zauber AG, et al (2006) Celecoxib for the prevention of sporadic colorec- tal adenomas. N Engl J Med 355:873–884
Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS (2005) Long-term use of aspirin and nonsteroidal anti- inflammatory drugs and risk of colorectal cancer. JAMA 294:914–923
Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS (2008) Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 134:21–28
Collet J P, Sharpe C, Belzile E, Boivin J F, Hanley J, Abenhaim L (1999) Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 81:62–68
Cook NR, Lee IM, Gaziano JM, et al (2005) Low- dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294:47–55
Croog VJ, Ullman TA, Itzkowitz SH (2003) Chemoprevention of colorectal cancer in ulcera- tive colitis. Int J Colorectal Dis 18:392–400
Dube C, Rostom A, Lewin G, et al (2007) The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146:365–375
DuPont AW, Arguedas MR, Wilcox CM (2007) Aspirin chemoprevention in patients with increased, risk for colorectal cancer: a cost-effectiveness analysis. Aliment Pharmacol Ther 26:431–441
Flossmann E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369:1603–1613
Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH (1993) Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85:1220–1224
Giardiello FM, Hamilton SR, Krush AJ, et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316
Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K (2003) A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adeno- matous polyposis patients. Clin Cancer Res 9:4756–4760
Hoffmeister M, Chang-Claude J, Brenner H (2007) Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population- based case-control study. Int J Cancer 121: 1325–1330
Juarranz M, Calle-Puron ME, Gonzalez-Navarro A, et al (2002) Physical exercise, use of Plantago ovata and aspirin, and reduced risk of colon cancer. Eur J Cancer Prev 11:465–472
Kune GA, Kune S, Watson LF (1988) Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48:4399–4404
Ladabaum U, Chopra CL, Huang G, Scheiman JM, Chernew ME, Fendrick AM (2001) Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med 135:769–781
Larsson SC, Giovannucci E, Wolk A (2006) Long- term aspirin use and colorectal cancer risk: a cohort study in Sweden. Br J Cancer 95:1277–1279
Lupulescu A (1996) Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot Essent Fatty Acids 54:83–94
Lynch HT, Thorson AG, Smyrk T (1995) Rectal cancer after prolonged sulindac chemoprevention. A case report. Cancer 75:936–938
Paganini-Hill A, Hsu G, Ross RK, Henderson BE (1991) Aspirin use and incidence of large-bowel cancer in a California retirement community. J Natl Cancer Inst 83:1182–1183
Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S (1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83:355–358
Rostom A, Dube C, Lewin G, et al (2007) Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146:376–389
Sandler RS, Halabi S, Baron JA, et al (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883–890
Sansbury LB, Millikan RC, Schroeder JC, Moorman PG, North KE, Sandler RS (2005) Use of nons- teroidal antiinflammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and whites. Am J Epidemiol 162:548–558
Steinbach G, Lynch PM, Phillips RK, et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952
Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH (1998) Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 128:713–720
Suleiman S, Rex DK, Sonnenberg A (2002) Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. Gastroenterology 122:78–84
Tangrea JA, Albert PS, Lanza E, et al (2003) Non- steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). Cancer Causes Control 14:403–411
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Baron, J.A. (2009). Aspirin and NSAIDs for the Prevention of Colorectal Cancer. In: Senn, HJ., Kapp, U., Otto, F. (eds) Cancer Prevention II. Recent Results in Cancer Research, vol 181. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69297-3_21
Download citation
DOI: https://doi.org/10.1007/978-3-540-69297-3_21
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-69296-6
Online ISBN: 978-3-540-69297-3
eBook Packages: MedicineMedicine (R0)